Krystal Biotech Inc - Asset Resilience Ratio
Krystal Biotech Inc (KRYS) has an Asset Resilience Ratio of 23.06% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Krystal Biotech Inc's Asset Resilience Ratio has changed over time. Check KRYS strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Krystal Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Krystal Biotech Inc (KRYS) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $322.09 Million | 23.06% |
| Total Liquid Assets | $322.09 Million | 23.06% |
Asset Resilience Insights
- Good Liquidity Position: Krystal Biotech Inc maintains a healthy 23.06% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Krystal Biotech Inc Industry Peers by Asset Resilience Ratio
Compare Krystal Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Krystal Biotech Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Krystal Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 24.85% | $331.49 Million | $1.33 Billion | +0.92pp |
| 2024-12-31 | 23.93% | $252.65 Million | $1.06 Billion | +2.69pp |
| 2023-12-31 | 21.24% | $173.85 Million | $818.36 Million | -17.66pp |
| 2022-12-31 | 38.91% | $217.27 Million | $558.45 Million | +23.44pp |
| 2021-12-31 | 15.46% | $96.85 Million | $626.29 Million | +14.50pp |
| 2020-12-31 | 0.96% | $2.99 Million | $310.84 Million | -1.99pp |
| 2019-12-31 | 2.95% | $6.17 Million | $209.02 Million | -4.02pp |
| 2018-12-31 | 6.97% | $8.09 Million | $116.12 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $50.11 Million | -- |
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystro… Read more